AstraZeneca CEO Says Summit Drug Could Drive Next Generation of Cancer Combinations After $2 Billion Investment
5 Articles
5 Articles
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
AstraZeneca finalises $2 billion Summit Therapeutics investment to accelerate ivonescimab combination development
Investment will support development of the PD-1/VEGF bispecific with sonesitatug vedotin and other AstraZeneca cancer medicines, including additional ADCs IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics, with the funding intended to accelerate development … Read the full press release →
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
MIAMI, Oct 5 — Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a [...]
AstraZeneca invests $2 billion in biotech company Summit Therapeutics.
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
